Antiviral treatment for cytomegalovirus eye inflammation
Treatments studied
Part of Eyes & vision, Infections clinical trials.
This study tests whether antiviral medicine can control eye inflammation caused by the cytomegalovirus (CMV). It has two parts: one for people with active inflammation and one for those whose inflammation has calmed down, to see if the medicine helps prevent it from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (20 in Thailand and Taiwan).
- For Part 1: You must have active inflammation in the front of your eye (anterior uveitis) that the doctor thinks is caused by a virus, and a test must confirm CMV in the fluid of your eye.
- For Part 2: You must have had CMV eye inflammation confirmed in the past, and your eye must be calm for at least 2 weeks before joining.
- You cannot have taken antiviral medicine within 14 days before starting.
- You cannot have a weakened immune system from HIV, organ transplant, or certain medications.
- You must be willing to follow the study schedule and use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This trial tests a study drug called artesunate as a possible new treatment for CMV (a common virus) in people who have had a kidney, lung, heart, or liver transplant. It is for patients whose CMV infection requires treatment with standard antivirals like ganciclovir or valganciclovir.
This early-phase study tests high-concentration ganciclovir eye drops to treat cytomegalovirus (CMV) retinitis, a serious eye infection. It may help people who are hard to treat with regular (systemic) antiviral medicine or who face higher risks with an injection directly into the eye.
This trial tests whether valganciclovir, an antiviral medicine, can help people with advanced HIV who have CMV in their blood but no CMV disease. The goal is to see if the medicine can reduce the amount of CMV and improve health.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Hear when a new Cytomegalovirus (CMV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.